mitoxantrone has been researched along with Astrocytoma, Grade IV in 13 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the safety and feasibility of a novel form of treatment offered by the direct intraoperative application of a Surgifoam-mitoxantrone mix into a glioblastoma multiforme postresection cavity." | 9.12 | Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note. ( Boiardi, A; Broggi, G; Broggi, M; Ferroli, P; Franzini, A; Lamperti, M; Maccagnano, E, 2006) |
| " To better characterize the mechanisms of ABCG2 overexpression, SF295 glioblastoma cells were exposed to increasing amounts of mitoxantrone to generate the SF295 MX50, MX100, MX250, and MX500 sublines, maintained in mitoxantrone concentrations ranging from 50 to 500 nmol/L." | 7.73 | Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma cells. ( Bates, SE; Honjo, Y; Huff, L; Hung, J; Knutsen, T; Rao, VK; Ried, T; Robey, RW; Wangsa, D, 2005) |
| "To investigate the safety and feasibility of a novel form of treatment offered by the direct intraoperative application of a Surgifoam-mitoxantrone mix into a glioblastoma multiforme postresection cavity." | 5.12 | Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note. ( Boiardi, A; Broggi, G; Broggi, M; Ferroli, P; Franzini, A; Lamperti, M; Maccagnano, E, 2006) |
| " To better characterize the mechanisms of ABCG2 overexpression, SF295 glioblastoma cells were exposed to increasing amounts of mitoxantrone to generate the SF295 MX50, MX100, MX250, and MX500 sublines, maintained in mitoxantrone concentrations ranging from 50 to 500 nmol/L." | 3.73 | Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma cells. ( Bates, SE; Honjo, Y; Huff, L; Hung, J; Knutsen, T; Rao, VK; Ried, T; Robey, RW; Wangsa, D, 2005) |
| "Chemosensitivity of previously untreated glioblastomas to mitoxantrone, methotrexate, ACNU and BCNU was tested on cultured tissue." | 3.70 | Multidrug resistance in glioblastoma. Chemosensitivity testing and immunohistochemical demonstration of P-glycoprotein. ( Damian, MS; Leweke, F; Schachenmayr, W; Schindler, C, 1998) |
| "We treated 54 patients, newly diagnosed for glioblastoma, with systemic chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks) and radiotherapy soon after surgery." | 3.70 | Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. ( Boiardi, A; Broggi, G; Eoli, M; Pozzi, A; Salmaggi, A; Silvani, A, 1999) |
| "Valproic acid (VPA) has been recently investigated for its anticancer properties in different tumors, including malignant gliomas." | 1.34 | Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines. ( Balzarotti, M; Boiardi, A; Calatozzolo, C; Ciusani, E; Croci, D; de Grazia, U; Salmaggi, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Senbabaoglu, F | 1 |
| Cingoz, A | 1 |
| Kaya, E | 1 |
| Kazancioglu, S | 1 |
| Lack, NA | 1 |
| Acilan, C | 1 |
| Bagci-Onder, T | 1 |
| Gopinath, SC | 1 |
| Wadhwa, R | 1 |
| Kumar, PK | 1 |
| Bhatia, P | 1 |
| Bernier, M | 1 |
| Sanghvi, M | 1 |
| Moaddel, R | 1 |
| Schwarting, R | 1 |
| Ramamoorthy, A | 1 |
| Wainer, IW | 1 |
| Boiardi, A | 7 |
| Bartolomei, M | 2 |
| Silvani, A | 5 |
| Eoli, M | 5 |
| Salmaggi, A | 6 |
| Lamperti, E | 4 |
| Milanesi, I | 1 |
| Botturi, A | 4 |
| Rocca, P | 1 |
| Bodei, L | 1 |
| Broggi, G | 6 |
| Paganelli, G | 1 |
| Rao, VK | 1 |
| Wangsa, D | 1 |
| Robey, RW | 1 |
| Huff, L | 1 |
| Honjo, Y | 1 |
| Hung, J | 1 |
| Knutsen, T | 1 |
| Ried, T | 1 |
| Bates, SE | 1 |
| Bissola, L | 1 |
| Finocchiaro, G | 1 |
| Ferroli, P | 1 |
| Broggi, M | 1 |
| Franzini, A | 1 |
| Maccagnano, E | 1 |
| Lamperti, M | 1 |
| Ciusani, E | 1 |
| Balzarotti, M | 1 |
| Calatozzolo, C | 1 |
| de Grazia, U | 1 |
| Croci, D | 1 |
| Gaviani, P | 1 |
| Fiumani, A | 1 |
| Falcone, C | 1 |
| Solari, A | 1 |
| Filippini, G | 1 |
| Di Meco, F | 1 |
| Senkal, M | 1 |
| Tonn, JC | 1 |
| Schönmayr, R | 1 |
| Schachenmayr, W | 2 |
| Eickhoff, U | 1 |
| Kemen, M | 1 |
| Kollig, E | 1 |
| Leweke, F | 1 |
| Damian, MS | 1 |
| Schindler, C | 1 |
| Pozzi, A | 1 |
3 trials available for mitoxantrone and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Brain Neoplasms; Chemotherapy, | 2005 |
New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM).
Topics: Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Combined Modality | 2003 |
Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Br | 2006 |
10 other studies available for mitoxantrone and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme.
Topics: Antineoplastic Agents; Glioblastoma; Humans; Mitoxantrone | 2016 |
Expression of noncoding vault RNA in human malignant cells and its importance in mitoxantrone resistance.
Topics: Antineoplastic Agents; Base Sequence; Bone Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; G | 2010 |
Breast cancer resistance protein (BCRP/ABCG2) localises to the nucleus in glioblastoma multiforme cells.
Topics: Astrocytoma; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transport | 2012 |
Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma cells.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Lin | 2005 |
Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Sur | 2005 |
Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Astrocytoma; Carmustine; Cel | 2007 |
Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
Topics: Adult; Aged; Aging; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combi | 2008 |
Mitoxantrone-induced DNA strand breaks in cell-cultures of malignant human astrocytoma and glioblastoma tumors.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; DNA Damage; DNA, Neoplasm; Glioblastoma; Humans; Middl | 1997 |
Multidrug resistance in glioblastoma. Chemosensitivity testing and immunohistochemical demonstration of P-glycoprotein.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member | 1998 |
Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy | 1999 |